


# DIANES TERAPEUTIQUES I REGULACIÓ DE LA MORT CEL·LULAR EN NEOPLASIES LIMFOIDES

## Membres del Grup:

Dolors Colomer, PhD  
Gaël Roué, PhD  
Roberto Alonso, PhD  
Patricia Perez-Galan, PhD  
Mónica Lopez-Guerra, llicenciada en Biologia  
Silvia Xargay, llicenciada en Biologia  
Laia Rosich, llicenciada en Biologia  
Sandra Cabezas, tècnic laboratori  
Laura Jimenez, tècnic laboratori



## Temàtica de la recerca. Presentació o resum

Anàlisi de noves estratègies terapèutiques en neoplàsies limfoides B, bàsicament en el limfoma de cèl·lules del mantell (LCM) i en la leucèmia limfàtica crònica (LLC). Estudi de les vies de senyalització implicades i del mecanisme d'acció dels fàrmacs. Aquests estudis es realitzen en línees cel·lulars i en cèl·lules primàries obtingudes de malalts diagnosticats d'aquestes hemopaties utilitzant fàrmacs.

## Publicacions destacables

1: Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E, Colomer D. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.

**Clin Cancer Res. 2008 Nov 1;14(21):6907-15. PMID: 18980985**

2: López-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M. Identification of TIGAR in the equilibrative nucleoside transporter 2 mediated response to fludarabine in chronic lymphocytic leukemia cells.  
**Haematologica. 2008 Dec;93(12):1843-51.** PMID: 18945750

3: Pérez-Galán P, Roué G, López-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclox) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.  
**Leukemia. 2008 Sep;22(9):1712-20.** PMID: 18596739

4: Roué G, Pichereau V, Lincet H, Colomer D, Sola B. Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators.  
**Oncogene. 2008 Aug 21;27(36):4909-20.** PMID: 18438428

5: Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.  
**Nat Rev Cancer. 2007 Oct;7(10):750-62.** PMID: 17891190

6: Roué G, Pérez-Galán P, López-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of I $\kappa$ B kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level.  
**J Immunol. 2007 Feb 1;178(3):1923-30.** PMID: 17237443

7: Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.  
**Blood. 2007 May 15;109(10):4441-9.** PMID: 17227835

8: Marcé S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.  
**Haematologica. 2006 Jul;91(7):895-902.** PMID: 16818276

9: Marcé S, Balagué O, Colomo L, Martínez A, Höller S, Villamor N, Bosch F, Ott G, Rosenwald A, Leoni L, Esteller M, Fraga MF, Montserrat E, Colomer D, Campo E. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.  
**Clin Cancer Res. 2006 Jun 15;12(12):3754-61.** PMID: 16778103

10: Salaverria I, Perez-Galan P, Colomer D, Campo E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives.  
**Haematologica. 2006 Jan;91(1):11-6.** PMID: 16434365

11: Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.  
**Blood. 2006 Jan 1;107(1):257-64.** PMID: 16166592

12: Molina-Arcas M, Marcé S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B, Montserrat E, Gil J, Colomer D, Pastor-Anglada M. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.  
**Leukemia. 2005 Jan;19(1):64-8.** PMID: 15510196

13: Ferrer A, Marcé S, Bellosillo B, Villamor N, Bosch F, López-Guillermo A, Espinet B, Solé F, Montserrat E, Campo E, Colomer D. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.  
**Oncogene. 2004 Nov 25;23(55):8941-9.** PMID: 15480431

14: Villamor N, Montserrat E, Colomer D. Cytotoxic effects of B lymphocytes mediated by reactive oxygen species.

**Curr Pharm Des.** 2004;**10(8):841-53**. PMID: 15040354

15: Martinez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival.

**Am J Pathol.** 2004 Feb;**164(2):501-10**. PMID: 14742256

16: Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukaemia.

**Leukemia.** 2004 Mar;**18(3):385-93**. PMID: 14737075

17: Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy.

**Semin Oncol.** 2003 Aug;**30(4):424-33**. PMID: 12939711

18: Campàs C, Dalmau M, Montaner B, Barragán M, Bellosillo B, Colomer D, Pons G, Pérez-Tomás R, Gil J. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia.

**Leukemia.** 2003 Apr;**17(4):746-50**. PMID: 12682632

19: Campàs C, Lopez JM, Santidrián AF, Barragán M, Bellosillo B, Colomer D, Gil J. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.

**Blood.** 2003 May 1;**101(9):3674-80**. PMID: 12522004

20: Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D, Pastor-Anglada M. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.

**Blood.** 2003 Mar 15;**101(6):2328-34**. PMID: 12411296

21: Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Bosch F, Campo E, Montserrat E, Colomer D. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.

**Blood.** 2002 Sep 1;**100(5):1810-6**. PMID: 12176904

22: Barragán M, Bellosillo B, Campàs C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.

**Blood.** 2002 Apr 15;**99(8):2969-76**. PMID: 11929788

23: Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, Colomer D, Montserrat E. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.

**Blood.** 2001 Nov 1;**98(9):2771-7**. PMID: 11675350